for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc (ADR)

AZN.N

Latest Trade

47.85USD

Change

-1.48(-3.00%)

Volume

566,051

Today's Range

47.40

 - 

48.20

52 Week Range

37.12

 - 

51.54

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
49.33
Open
48.15
Volume
566,051
3M AVG Volume
55.18
Today's High
48.20
Today's Low
47.40
52 Week High
51.54
52 Week Low
37.12
Shares Out (MIL)
1,312.14
Market Cap (MIL)
124,957.20
Forward P/E
--
Dividend (Yield %)
3.87

Next Event

AstraZeneca PLC Investor Roadshow - Europe and US

Latest Developments

More

AstraZeneca CEO says not seen operational disruption in China

AstraZeneca Says 2020 Rev Growth To Depend On Impact Of Coronavirus

Cellink Announces Extension Of Collaboration With Astrazeneca

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc (ADR)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Contact Info

1 Francis Crick Avenue

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Fiona Cicconi

Executive Vice President - Human Resources

Key Stats

1.50 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.5K

2018

22.1K

2019

24.4K

2020(E)

27.0K
EPS (USD)

2017

2.140

2018

1.730

2019

1.750

2020(E)

2.065
Price To Earnings (TTM)
92.64
Price To Sales (TTM)
5.12
Price To Book (MRQ)
9.57
Price To Cash Flow (TTM)
25.05
Total Debt To Equity (MRQ)
138.85
LT Debt To Equity (MRQ)
123.54
Return on Investment (TTM)
2.90
Return on Equity (TTM)
2.01

Latest News

Latest News

UPDATE 2-FTSE 100 ends week lower after week AstraZeneca, RBS results

* Coronavirus spread fuels stimulus hopes (Adds company news items, updates share moves)

AstraZeneca 2020 forecasts hit by coronavirus, shares dive

British drugmaker AstraZeneca <AZN.L> forecast revenue growth for this year of around 10% on Friday, as it factored in a hit from the coronavirus outbreak in China and fell short of analysts' expectations for fourth-quarter results.

AstraZeneca's CEO reaffirms 2021 targets

AstraZeneca <AZN.L> is fully on track to reach its earnings goal for next year, its chief executive told Reuters on Friday after the British drugmaker's quarterly earnings missed market expectations.

BRIEF-AstraZeneca CEO says not seen operational disruption in China

* ASTRAZENECA CEO SAYS OVERALL HAVE NOT SEEN DISRUPTION IN OPERATIONS IN CHINA - CONF CALL

FTSE slips on poor earnings from AstraZeneca, RBS

UK blue-chip shares slipped further on Friday, weighed down by underwhelming results from AstraZeneca and RBS, while investors remained unsettled due to concerns over the impact of the coronavirus on the global economy.

BRIEF-AstraZeneca Says 2020 Rev Growth To Depend On Impact Of Coronavirus

* ASTRAZENECA - ALL GUIDANCE ASSUMES UNFAVOURABLE IMPACT FROM CHINA LASTING UP TO A FEW MONTHS AS A RESULT OF RECENT NOVEL CORONAVIRUS OUTBREAK

AstraZeneca says 2020 sales growth to take coronavirus hit

AstraZeneca expects 2020 revenue growth in the high single-digit to low double-digit percentages, including a hit it now expects from the coronavirus outbreak in China, its second biggest market, the British drugmaker said on Friday.

CORRECTED-BRIEF-Starpharma Holdings Says Receives $3 Mln Milestone From AstraZeneca

* RECEIVED $3 MILLION FROM ASTRAZENECA AFTER SUCCESSFUL DOSING OF FIRST PATIENT IN PHASE1 CLINICAL TRIAL OF AZD0466 IN DEC Source text https://reut.rs/2OJaYua Further company coverage:

AbbVie-Allergan $63 billion deal aided by Nestle, AstraZeneca buys

U.S. drugmaker AbbVie's <ABBV.N> $63 billion tie-up with Allergan <AGN.N> is getting help from Nestle <NESN.S> and AstraZeneca <AZN.L> buying up products the Irish-domiciled company is shedding to placate regulators.

AstraZeneca to discontinue Epanova trial, expects $100 million writedown

AstraZeneca said on Monday it will discontinue a late-stage trial for heart disease drug Epanova to treat patients with mixed dyslipidaemia and expects a $100 million writedown to hit its core profit in the fourth quarter.

AstraZeneca to discontinue Epanova trial, expects $100 mln writedown

AstraZeneca said on Monday it will discontinue a late-stage trial for Epanova to treat patients with mixed dyslipidaemia at high risk of cardiovascular disease and expects a $100 million writedown to hit its core profit in the fourth quarter.

AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer

AstraZeneca and Merck's ovarian cancer drug Lynparza has received U.S. regulatory approval for the treatment of advanced pancreatic cancer, cementing its lead in a niche category of cancer treatments.

AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer

Dec 30 - AstraZeneca Plc and Merck & Co's ovarian cancer drug, Lynparza, was approved by U.S. regulators for the treatment of advanced pancreatic cancer in patients with BRCA gene mutations, the British drugmaker said on Monday.

AstraZeneca, Daiichi's breast cancer drug gets accelerated approval from FDA

(This Dec.20 story corrects first paragraph to say the approval came four months ahead of schedule, not three months, after FDA clarification)

AstraZeneca-Daiichi drug halts cancer for months in first readout

An experimental cancer drug developed by AstraZeneca and Daiichi Sankyo kept metastatic breast cancer at bay for months in women who had exhausted other treatment options, its first clinical study showed.

AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a form of ovarian cancer.

AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancer

British drugmaker AstraZeneca Plc said on Friday its immunotherapy cancer treatment Imfinzi has been granted a speedy review by the U.S. medicines watchdog for the treatment of a particularly aggressive type of lung cancer.

RPT-AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer

British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.

AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer

British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.

AstraZeneca shares rise on early U.S. approval for leukemia drug

AstraZeneca <AZN.L> shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukemia drug, in a challenge to rival AbbVie <ABBV.N>.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up